Compare Banco Santander SA (SAN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Summit Therapeutics Inc — how do they compare? Banco Santander SA trades at $13.49 (market cap $192.86B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Banco Santander SA is far larger — about 14.1× Summit Therapeutics Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Summit Therapeutics Inc for 16 Days on average.
| SAN | SMMT | |
|---|---|---|
Market Cap | $192.86B | $13.71B |
Volume | 10,644,519 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $15.05 | $26.38 |
52-Week Low | $9.65 | $12.43 |
Typical Hold Time | 55 Days | 16 Days |
Enterprise Value | $360.86B | $13.04B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.48, down 1.32% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss. Fundamentals are solid with a 26.25% net income margin and a P/E of 13.55, while cash flow trends have weakened significantly. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence.
The outlook is cautiously optimistic given strong profitability and analyst support, but risks include declining cash flows, high debt levels, and economic sensitivity. The stock's current valuation may appeal to value-oriented investors, though near-term volatility is likely.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
